Abstract:Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature post-thymic T-cell. The contemporary World Health Organization (WHO) Classification of Haematologic Malignancies recognizes two distinct subtypes of systemic ALCL: Anaplastic Lymphoma Kinase (ALK)-negative, and ALK-positive. An additional unique subtype of ALCL is known to arise after prolonged exposure to breast implants, known as Breast Implant Associated ALCL (BIALCL). While histologic features of ALCL subtypes have significant overlap, genomic studies suggest the unique pathophysiology and molecular events of tumorigenesis. As a group, ALCLs are rare among non-Hodgkin lymphomas comprising 1-3% overall. There seems to be age and geographic predilection with ALK-positive ALCL affecting younger individuals and being diagnosed more frequently in North America than Europe. Both subtypes are quite uncommon in Hispanic and Asian populations. ALK-positive ALCL patients have a better overall prognosis than those with ALK-negative ALCL, and clinical features at presentation (i.e., International Prognostic Index, IPI) define the outcome in both subtypes. Molecular events affecting DUSP22 and TP63 have been reported to predict survival outcomes as well, with former being favorable, and the latter an unfavorable prognostic marker. Multiagent CHOP-like chemotherapy remains a standard of care for newly diagnosed ALCL patients treated with curative intent and provide a chance of cure for the majority of ALK-positive ALCL patients, and at least half of the ALK-negative ALCL patients. The role of consolidative high-dose therapy and autologous hematopoietic stem cell transplantation remains unclear. Novel targeted agents are actively being investigated for their role in initial therapy. New immunoconjugates, targeted kinase inhibitors, and transgenic autologous T-cells are being studied in patients with relapsed and refractory disease. This review will discuss contemporary concepts in pathogenesis and management of systemic ALCL. The biology and management of primary cutaneous ALCL will be discussed elsewhere.

Skin-limited relapse of systemic anaplastic large-cell lymphoma

Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma

ALK-negative Anaplastic Large Cell Lymphoma with Extensive Peripheral Blood and Bone Marrow Involvements Manifested As "leukemic Phase".

Detection of TRAF1-ALK fusion in skin lesions of systemic ALK+ anaplastic large cell lymphoma initially involving the skin and the draining lymph node

ALCL by any other name: the many facets of anaplastic large cell lymphoma

Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma

The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)

Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment

Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report

Gene rearrangement in T-cell receptor γ and immunoglobulin heavy chain for primary cutaneous anaplastic large cell lymphoma

Non-Hodgkin's Anaplastic Large T-Cell Lymphoma: A Case Report

Updates in pathobiological aspects of anaplastic large cell lymphoma

A Case of Central Nervous System Metastasis of Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma Manifested As Central Nervous System Vasculitis

ALK-positive large B-cell lymphoma showing long-term response to conventional chemoradiotherapy

A Rare and Isolated Presentation of Primary Cutaneous Anaplastic Large Cell Lymphoma on the Breast

Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management

Systemic ALK-negative anaplastic large cell lymphoma with NPM1::TYK2 rearrangement

Clinicopathological Study of Cutaneous Anaplastic Large Cell Lymphoma Complicated with Acute Myeloid Leukemia

Clinical characteristic and treatment of 8 children anaplastic large cell lymphoma

Pathology and genetics of anaplastic large cell lymphoma

[Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement]